Therefore, particularly patients with bilateral renal AML should be referred for further testing for TSC, especially in light of the recent changes in the management of TSC and the option of a disease targeted therapy with mTOR-Inhibitors [13]. The gene discussed is TSC1; the disease is tuberous sclerosis.